Logo image of CAI

CARIS LIFE SCIENCES INC (CAI) Stock Fundamental Analysis

USA - NASDAQ:CAI - US1421521071 - Common Stock

33.495 USD
-0.57 (-1.66%)
Last: 9/15/2025, 1:39:02 PM
Fundamental Rating

3

CAI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 540 industry peers in the Biotechnology industry. CAI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CAI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CAI had negative earnings in the past year.
In multiple years CAI reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CAI reported negative operating cash flow in multiple years.
CAI Yearly Net Income VS EBIT VS OCF VS FCFCAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

Looking at the Return On Assets, with a value of -39.61%, CAI is in line with its industry, outperforming 59.26% of the companies in the same industry.
With a Return On Equity value of -83.52%, CAI perfoms like the industry average, outperforming 50.93% of the companies in the same industry.
Industry RankSector Rank
ROA -39.61%
ROE -83.52%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CAI Yearly ROA, ROE, ROICCAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

With a decent Gross Margin value of 43.77%, CAI is doing good in the industry, outperforming 74.81% of the companies in the same industry.
CAI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAI Yearly Profit, Operating, Gross MarginsCAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2023 2024 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

CAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
CAI has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for CAI has been increased compared to 5 years ago.
CAI has a worse debt/assets ratio than last year.
CAI Yearly Shares OutstandingCAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2023 2024 50M 100M 150M 200M 250M
CAI Yearly Total Debt VS Total AssetsCAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 8.03 indicates that CAI is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.03, CAI belongs to the top of the industry, outperforming 82.04% of the companies in the same industry.
CAI has a Debt/Equity ratio of 0.82. This is a neutral value indicating CAI is somewhat dependend on debt financing.
CAI's Debt to Equity ratio of 0.82 is on the low side compared to the rest of the industry. CAI is outperformed by 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Altman-Z 8.03
ROIC/WACCN/A
WACC9.84%
CAI Yearly LT Debt VS Equity VS FCFCAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 9.24 indicates that CAI has no problem at all paying its short term obligations.
CAI's Current ratio of 9.24 is fine compared to the rest of the industry. CAI outperforms 78.89% of its industry peers.
A Quick Ratio of 8.79 indicates that CAI has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.79, CAI is doing good in the industry, outperforming 76.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.24
Quick Ratio 8.79
CAI Yearly Current Assets VS Current LiabilitesCAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.22% over the past year.
The Revenue has grown by 34.67% in the past year. This is a very strong growth!
Measured over the past years, CAI shows a small growth in Revenue. The Revenue has been growing by 6.64% on average per year.
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -28.69% on average over the next years. This is quite bad
Based on estimates for the next years, CAI will show a very strong growth in Revenue. The Revenue will grow by 36.53% on average per year.
EPS Next Y-121.74%
EPS Next 2Y-79.53%
EPS Next 3Y-47.13%
EPS Next 5Y-28.69%
Revenue Next Year63.34%
Revenue Next 2Y54.33%
Revenue Next 3Y43.5%
Revenue Next 5Y36.53%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CAI Yearly Revenue VS EstimatesCAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B
CAI Yearly EPS VS EstimatesCAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 114.09, the valuation of CAI can be described as expensive.
Based on the Price/Forward Earnings ratio, CAI is valued cheaper than 87.59% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.73. CAI is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 114.09
CAI Price Earnings VS Forward Price EarningsCAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAI Per share dataCAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

CAI's earnings are expected to decrease with -47.13% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-79.53%
EPS Next 3Y-47.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CAI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARIS LIFE SCIENCES INC

NASDAQ:CAI (9/15/2025, 1:39:02 PM)

33.495

-0.57 (-1.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)N/A N/A
Inst Owners11.45%
Inst Owner Change40775.2%
Ins Owners49.48%
Ins Owner Change9.39%
Market Cap9.42B
Analysts87.69
Price Target39.91 (19.15%)
Short Float %1.52%
Short Ratio2.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)18.56%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 114.09
P/S 22.85
P/FCF N/A
P/OCF N/A
P/B 20.8
P/tB 21.73
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)0.29
Fwd EY0.88%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.47
BVpS1.61
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.61%
ROE -83.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.77%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.24
Quick Ratio 8.79
Altman-Z 8.03
F-ScoreN/A
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-121.74%
EPS Next 2Y-79.53%
EPS Next 3Y-47.13%
EPS Next 5Y-28.69%
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A
Revenue Next Year63.34%
Revenue Next 2Y54.33%
Revenue Next 3Y43.5%
Revenue Next 5Y36.53%
EBIT growth 1Y19.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year74.35%
EBIT Next 3Y47.44%
EBIT Next 5Y34.98%
FCF growth 1Y15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.19%
OCF growth 3YN/A
OCF growth 5YN/A